Given the availability of an increasing number of approved innovative, high-cost gene therapies, value assessment and novel approaches to reimbursement are rapidly gaining importance. To assist developers of gene therapies in planning for market access challenges, this study analyzes MCO reimbursement policies and their effect on physicians\u2019 prescribing of gene therapies that treat the neuromuscular diseases spinal muscular atrophy (SMA), Duchenne muscular dystrophy (DMD), and cerebral adrenoleukodystrophy (CALD) and the hematological disorder beta thalassemia. In this report, we examine commercial plan coverage of and restrictions on several marketed therapies\u2014including Novartis\u2019s Zolgensma for SMA, Sarepta Therapeutics\u2019 Elevidys for DMD, Bluebird Bio\u2019s Skysona for CALD, and Zynteglo for beta thalassemia, as well as Vertex Pharmaceuticals \/ CRISPR Therapeutics\u2019 Casgevy\u2014and assess the market access potential for late-phase gene replacement therapies.<\/p>\n
Questions answered<\/strong><\/p>\n Product description<\/strong><\/p>\n Leveraging Clarivate\u2019s proprietary data sources and surveys with physicians and payers, Access & Reimbursement provides integrated brand- and disease-level insight on reimbursement dynamics and the impact of payer policy on physician prescribing behavior in the United States. Through detailed analyses of drug coverage, restriction policies, and contracting, as well as payer and prescriber perspectives on key marketed drugs and their receptivity to emerging therapies, this report enables you to:<\/p>\n\n
\n